Kythera Pharmaceuticals Purchases Rights to PGD2 Blocking Drug “Setipriprant” for Hair Loss
Last week, Kythera pharmaceuticals purchased the rights to “setipriprant,” a prostaglandin D2 (PGD2) drug for the treatment of hair loss. The PGD2 theory of hair loss was initially proposed by Dr. George Cotsarelis at the University of Pennsylvania in 2012. Cotsarelis and his team found elevated PGD2 levels in bald scalp compared to non-balding scalp. Cotsarelis […]
